NBCD

Looking for expert insights into clinical trials for rheumatic diseases? 🧬 At the forefront of the development of new science to change in future of arthritis treatments, we are once again contributing actively to the newest data in rheumatology at the American College of Rheumatology (ACR) Convergence 2024 in Washington DC. This year we, with our excellent partners, are co-authoring four abstracts, of which one is a late-breaking oral presentation, highlighting the importance of the data presented. Take the opportunity to meet with our Chief Scientific Officer, Asger Bihlet, if you are looking for expert advice on clinical trials in rheumatic diseases. #ACR2024 #Rheumatology #ClinicalTrials #partofSanosGroup  

We are super excited to share that our pioneering trial, PAKOA-001, has successfully screened and randomized its first participants at the Sanos Clinic in Herlev, Denmark! 🎉 PAKOA-001 is the first study to evaluate an innovative and easy-to-use approach for managing treatment expectations within a placebo-controlled trial, with the intent of reducing the placebo response and increase our ability to detect true effects of efficacious treatments. Through advanced sensory testing and detailed patient-reported measures, this project will provide critical insights into how study participants report their pain and how that affects the placebo response - insights that could transform how clinical trials are conducted worldwide. With a goal to enroll 150 participants across our three Sanos Clinics, this study reflects our commitment to making a meaningful impact on new treatment possibilities for patients in need. Led by our PhD Fellow Jakob Mejdahl Bentin, MD, supported by the NBCD and Sanos Science team, the project is partially funded by the Innovation Foundation Denmark. We’re also honored to collaborate with top experts, including Prof. Lars Arendt-Nielsen, a global expert in pain research at Aalborg University, and Prof. Lene Vase from Aarhus University, a global thought-leading scientist on placebo effects. At Sanos Group we are dedicated to advancing science and creating solutions that make a real difference. Stay tuned for more milestones to come! #ClinicalTrials #PlaceboResearch #NBCD #PatientImpact #partofSanosGroup  

Proud to have the NBCD/Sanos Group and Sanos Clinic teams featured in this month's top OA journal. Also big thanks to Stryker - Imorphics and Alan Brett PhD for the very important contributions to the trial. The conclusion is that the trial was great, but the investigational product did not appear to be associated with any benefits in OA - we will keep working to develop new treatments for this massive medical need now and in the future.

Are you ready to make a true impact in clinical research? Join NBCD as a 𝗦𝗲𝗻𝗶𝗼𝗿 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹 𝗠𝗮𝗻𝗮𝗴𝗲𝗿! Check out the job post below, and reach out to Anne Bo Follin if you have any questions 🙌

Getting ready for #IASP ✈️ We’re thrilled to announce that NBCD is participating in the International Association for the Study of Pain (IASP) conference in Amsterdam, Netherlands! Join us as Jakob Mejdahl Bentin presents our latest findings in a poster session titled: "Characterizing Pain Rescue Medication Use in Knee Osteoarthritis Trials – a Post-hoc Analysis." This collaborative effort, with contributions from J. M. Bentin, L. Arendt-Nielsen, I. S. Adrian, P. Poudel, J. R. Andersen, A. Reynolds, A. Pavesio, H. Rovsing, B. Husøy, P. Alexandersen, and A. R. Bihlet, explores rescue medication usage patterns in knee osteoarthritis RCTs. By examining associations with clinical and demographic characteristics, our research aims to improve trial result interpretation and inform future trial designs. We invite you to join us at IASP to delve into these valuable insights. Jakob will be available to discuss our findings and their implications for pain management research. #IASP2024 #PainManagement #OsteoarthritisResearch #NBCD #partofSanosGroup

Join us in Vienna! 📢 NBCD and Sanos Group will be well-represented at this year’s EULAR conference in Vienna, Austria. Our expertise and significant contributions to the development of new treatments for osteoarthritis are evident, as NBCD and Sanos staff have co-authored four accepted abstracts, three of which have been accepted as oral presentations. Get in contact with our Chief Scientific Officer, Asger Bihlet, if you would like to meet and discuss how to succeed with clinical trials in OA. See you in Vienna! #EULAR2024 #Osteoarthritis #ClinicalTrials #ContractResearch #NBCD #partofSanosGroup

📅 NBCD is getting ready for #BIO2024! Just a few more days until the BIO International Convention in San Diego! NBCD will be represented by Chief Commercial Officer, Casper Clemmensen, who is ready to share our insights and engage in meaningful discussions with both current and potential partners. If you haven’t booked a meeting already, make sure to reach out here on LinkedIn or at ccl@nbcd.com. Looking forward to seeing you soon! #BIO #ContractResearch #Osteoarthritis #ClinicalDevelopment #NBCD #partofSanosGroup

Join our team at NBCD! 📢